Heparin-induced thrombocytopenia

References

• Chong BH. Heparin-induced thrombocytopenia. Br J Haematol 89, 431–439 (1995).
   PubMed Web of Science ®Google Scholar
• Warketin TE, Chong BH, Greinacher A. Heparin-induced thrombocytopenia: towards consensus. Thromb. Haemostas. 79, 1–7 (1998).
   PubMed Web of Science ®Google Scholar
• Chong BH, Pitney WR, Castaldi PA. Heparin-induced thrombocytopenia: association of thrombotic complication with a heparin-dependent IgG antibody which induced platelet aggregation, release and thromboxane synthesis. Lancetll, 1246–1248 (1982).
   Google Scholar
• ••First report of two clinical types ofheparin-induced thrombocytopenia (HIT): Type I, no detectable HIT antibody and patients are asymptomatic; Type II, HIT antibody detectable and patients frequently have associated thrombotic complications.
   Google Scholar
• Chong BH, Ismail E The mechanism of heparin-induced platelet aggregation. Eur J. Haematol 43, 245–251 (1989).
   PubMed Web of Science ®Google Scholar
• Burgess JK, Chong BH. The platelet proaggregating and potentiating effects of unfractionated heparin, low-molecular-weight heparin and heparinoid in intensive care patients and healthy controls. Eur. Haematol 58, 270–285 (1997).
   Web of Science ®Google Scholar
• Mikhaildis DP Barradas MA, Jeremy JY, Gracey L, Wakeling A, Dandona P Heparin-induced platelet aggregation in anorexia nervosa and in severe peripheral vascular disease. Eur.J. ain. Invest. 15, 313–319 (1985).
   PubMed Web of Science ®Google Scholar
• Amiral J, Bridey F, Dreyfus M et al Platelet Factor 4 complexed to heparin is the target for 95–96 (1992).
   Google Scholar
• ••First report to show that the antibody inHIT is directed against the platelet factor (PF) 4-heparin complex.
   Google Scholar
• Bell WR, Royall RM. Heparin-associatedthrombocytopenia: a comparison of three heparin preparations. N Engl J. Med 303, 902–907 (1980).
   PubMed Web of Science ®Google Scholar
• Bailey RTJ, Ursick JA, Heim KL, Hilleman DE, Reich JW Heparin-associated Drug Intel Clin. Pharm. 20, 374–378 (1986).
   PubMedGoogle Scholar
• Warkentin TE, Levine MN, Hirsh J et al Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332, 1330–1335 (1995).
   PubMed Web of Science ®Google Scholar
• ••Incidence of HIT is low in patientsreceiving low-molecular-weight heparin
   Google Scholar
• Cipolle RJ, Rodvold KA, Seifert R, Clarens R, Ramirez-Lassepas M. Heparin-associated thrombocytopenia: a prospective evaluation of 211 patients. Ther. Drug Monit. 5, 205–211 (1983).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 96, 1703–1708 (2000).
   PubMed Web of Science ®Google Scholar
• ••Clearly demonstrates that the patient population has an impact on the risk of HIT. The authors found that patients who had undergone hip surgery were more likely to develop HIT than those who had cardiac surgery.
   Google Scholar
• Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, Inc., NY, USA, 107–148 (2004).
   Google Scholar
• Chong B. Heparin-induced thrombocytopenia. In: Platelets. Michelson A (Ed.), Academic Press, NY, USA, 571–591 (2002).
   Google Scholar
• Visentin GP, Ford SE, Scott JP, Aster RH. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet Factor 4 complexed with heparin or bound to endothelial cells. J. Clin. Invest. 93, 81–88 (1994). Confirms the earlier findings of Amiral and colleagues that the antigenic target of the HIT antibody is the PF4-heparin complex.
   PubMed Web of Science ®Google Scholar
• Newman E Chong BH. Heparin-induced thrombocytopenia: the major antigenic epitope is on the modified platelet Factor 4 and not on heparin. Br J HaematoL 107, 303–309 (1999).
   PubMedGoogle Scholar
• ••Shows convincingly that the epitope of theHIT antibody is on PF4 and not on heparin of the PF4—heparin complex.
   Google Scholar
• Fabris FAS, Cella G, Jeska W1 Walenga JM, Fareed J. Pathophysiology of heparin-induced thrombocytopenia. Clinical and diagnostic implications — a review. Arch. PathoL Lab. Med 124, 1657–1666 (2000).
   PubMed Web of Science ®Google Scholar
• Pouplard C, May MA, Iochmann S et al Antibodies to platelet Factor 4—heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin: clinical implications for heparin-induced thrombocytopenia. Circulation 99, 2530–3536 (1999).
   PubMed Web of Science ®Google Scholar
• •Shows a high frequency of anti-PF4/heparin antibodies in patients after cardiopulmonary bypass (CPB).
   Google Scholar
• Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac AM, Fressinaud E. High incidence of anti-heparin/platelet Factor 4 antibodies after cardiopulmonary bypass. Br J HaematoL 101,653–655 (1998).
   PubMed Web of Science ®Google Scholar
• •A further demonstration of the high frequency of anti-PF4/heparinantibodies in patients after CPB.
   Google Scholar
• Chong BH, Ismail F, Chesterman CN, Berndt MC. Heparin-induced thrombocytopenia: mechanism of interaction of the heparin-dependent antibody with platelets. Br J. HaematoL 73, 235–240 (1989).
   PubMed Web of Science ®Google Scholar
• ••Demonstrates that platelet activation by theHIT antibody is mediated via platelet FcyRII.
   Google Scholar
• Newman P, Chong BH. Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purtied anti-PF4—heparin antibodies to platelets and the resulting activation. Blood 96, 182–187 (2000).
   PubMed Web of Science ®Google Scholar
• ••HIT antibody binds to PF4—heparincomplexes on the platelet surface via its Fab domain after the antibody has induced PF4 release from the platelets.
   Google Scholar
• Kelton JG, Sheridan D, Santos A et al Heparin-induced thrombocytopenia: laboratory studies. B/ood72, 925–930 (1998).
   Google Scholar
• ••Platelet activation by the HIT antibody ismediated via platelet FcyRII.
   Google Scholar
• Warkentin TE, Hayward CPM, Boshkov LK et al Sera from patients with heparin-induced thrombocytopenia generated platelet-derived micropartides with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84, 3691–3699 (1994).
   PubMed Web of Science ®Google Scholar
• ••The HIT antibody can generate platelet-derived microparticles that have procoagulant activity.
   Google Scholar
• Chong BH, Grace CS, Rosenberg MC. Heparin-induced thrombocytopenia: effects of heparin platelet antibody on platelets. Brit. J HaematoL 49, 531–540 (1981).
   PubMed Web of Science ®Google Scholar
• ••First paper to show that the HIT antibodycan generate thromboxane A2, a potent platelet aggregating molecule, and can also produce platelet procoagulant activity without causing platelet lysis.
   Google Scholar
• Pouplard C, Iochmann S, Renard B, Herault O, Gruel Y. Induction of monocyte tissue factor expression by antibodies to heparin—platelet Factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 97, 3300–3302 (2001).
   PubMed Web of Science ®Google Scholar
• •Shows interaction of anti-PF4/heparin antibodies with monocytes leading to tissue factor expression.
   Google Scholar
• Arepally GM, Mayer IM. Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin 8. Blood 98, 1252–1254(2001).
   PubMed Web of Science ®Google Scholar
• •Demonstrates interaction of anti-PF4/heparin antibodies with monocytes leading to tissue factor expression.
   Google Scholar
• Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N EngL J Med 316, 581–589 (1987).
   PubMed Web of Science ®Google Scholar
• ••HIT antibody can bind to endothelial cellsand cause immunoinjury.
   Google Scholar
• Dawes J, Pumphrey CW, McLaren KM, Prowse CV, Pepper DS. The in vivo release of human platelet Factor 4 by heparin. Thromb. Res. 27, 65–76 (1982).
   PubMed Web of Science ®Google Scholar
• Home MKI, Chao ES. The effect of molecular weight on heparin binding to platelets. Br. J HaematoL 74, 306–312 (1990).
   PubMed Web of Science ®Google Scholar
• Home MM, Hutchinson KJ. Simultaneous binding of heparin and platelet Factor-4 to platelets: further insights into the mechanism of heparin-induced thrombocytopenia. Am. J HematoL 58, 24–30 (1998).
   PubMed Web of Science ®Google Scholar
• Visentin GP, Moghaddam M, Collins JL, McFarland JG, Aster RH. Antibodies associated with heparin-induced thrombocytopenia (HIT) report conformational changes in platelet Factor 4 (PF4) induced by linear polyanionic compounds. Blood 90(Suppl. 1), (1997) (Abstract 460a).
   Google Scholar
• Amiral J, Marfaing-Koka A, Wolf M et al Presence of auto-antibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated-thrombocytopenia. Blood 88, 410–416 (1996).
   PubMed Web of Science ®Google Scholar
• •Demonstrates that interleukin-8 or neutrophil-activating peptide-2 may also be the autoantigen in some patients with HIT.
   Google Scholar
• Greinacher A, Alban S, Dummel V, Franz G, Mueller-Eckhardt C. Characterization of the structural requirements for a carbohydrate based anticoagulant with a reduced risk of inducing the immunological type of heparin-associated thrombocytopenia. Thromb. Haemost. 74, 886–892 (1995).
   PubMed Web of Science ®Google Scholar
• Ahmad S, Haas S, Hoppensteadt DA et al Differential effects of divarin and heparin in patients undergoing hip and knee surgery for the generation of anti-heparin Factor 4 antibodies. Thromb. Res. 108, 49–55 (2002).
   PubMed Web of Science ®Google Scholar
• Visentin GP Malik M, Cyganiak KA, Aster RH. Patients treated with unfractionated heparin during open heart surgery are at high risk to form antibodies reactive with heparin platelet Factor 4 complexes. J. Lab. Clin. Med 128, 376–383 (1996).
   PubMed Web of Science ®Google Scholar
• •Shows a high frequency of anti-PF4/heparin antibodies in patients who undergo CPB.
   Google Scholar
• Amiral J, Wolf M, Fischer AM, Boyer- Neumann C, Vissac AM, Meyer D. Pathogenicity of IgA and/or IgIVI antibodies to heparin—PF4 complexes in patients with heparin-induced thrombocytopenia. Br. J HaematoL 92, 954–959 (1996).
   PubMed Web of Science ®Google Scholar
• Nelson JC, Lerner RG, Goldstein R, CAgin NA. Heparin-induced thromboctyopenia. Arch. Intern. Med 138, 548–552 (1978).
   PubMed Web of Science ®Google Scholar
• Warkentin TE. Clinical picture of HIT In: Heparin-Induced Thrombocytopenia. Warkentin TE , Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
   Google Scholar
• Warkentin TE, Hong AP Frequency of upper limb deep-venous thrombosis (UL-DVT) in relation to central venous catheter (CVC) use in patients with heparin-induced thrombocytopenia (HIT): evidence for interaction of systemic (HIT) and local (CVC) prothrombotic risk factors. Blood 92\(Suppl. 1), 500a-510a (1998) (Abstract).
   Google Scholar
• Natelson EA, Lynch EC, Alfrey CP Jr, Gross JB. Heparin-induced thrombocytopenia. An unexpected response to treatment of consumption coagulopathy. Ann. Intern. Med 71, 1121–1125 (1969).
   PubMed Web of Science ®Google Scholar
• Klein HG, Bell WR. Disseminated intravascular coagulation during heparin therapy. Intern. Med 80, 477–448 (1974).
   Web of Science ®Google Scholar
• Rhodes GR, Dixon RH, Silver D. Heparin- induced thrombocytopenia with thrombotic and hemorrhagic manifestations. Surg. GynecoL Obstet. 136, 409–416 (1973).
   PubMedGoogle Scholar
• ••One of the earlier papers that clearly demonstrates the association of disastrous thrombotic complications with HIT.
   Google Scholar
• Warkentin TE, Soutar RL, Panju A, Ginsberg JS. Acute systemic reactions to intravenous bolus heparin therapy: characterization and relationship to heparin-induced thrombocytopenia. Blood 80\(Suppl. 1), (1992) (Abstract 160a).
   Google Scholar
• Warkentin TE, Hirte HW, Anderson DR et al Transient global amnesia associated with acute heparin-induced thrombocytopenia. Am. J. Med. Sci. 97,489–491(1994).
   Google Scholar
• Greinacher A, Wakentin TE. Laboratory testing for heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
   Google Scholar
• Chong BH, Burgess J, Ismail E The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb. Haemost. 69, 344–350 (1993).
   PubMed Web of Science ®Google Scholar
• ••Clearly identifies the optimal experimentalconditions for the platelet aggregation test, showing that the test result can be affected by donor platelet variability, the heparin concentration and the immunoglobulin (Ig)G in plasma.
   Google Scholar
• Sheridan D, Carter C, Kelton JG. A diagnostic test for heparin-induced thrombocytopenia. Blood 67,27–30 (1986).
   PubMed Web of Science ®Google Scholar
• ••First description of the two-point 14Cserotonin release test, defining the experimental conditions for a specific and sensitive test for HIT.
   Google Scholar
• Greinacher A, Michels J, Kiefel V, Mueller- Eckhardt C. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb. Haemost. 66, 734–736 (1991).
   PubMed Web of Science ®Google Scholar
• ••First description of the heparin-inducedplatelet aggregation assay.
   Google Scholar
• Stewart MW, Etches WS, Boshkov LK, Gordon PA. Heparin-induced thrombocytopenia: an improved method of detection based on lumi-aggregometry. Br J. HaematoL 91,173–177 (1995).
   PubMed Web of Science ®Google Scholar
• Tomer A. A sensitive and specific functional flow cytometric assay for the diagnosis of heparin-induced thrombocytopenia. Br. J HaematoL 98,648–656 (1997).
   PubMed Web of Science ®Google Scholar
• •First description of a flow cytometry test for HIT.
   Google Scholar
• Tomer A, Masalunga C, Abshire TC. Determination of heparin-induced thrombocytopenia: a rapid flow cytometric assay for direct demonstration of antibody-mediated platelet activation. Am. J. HematoL 61,53–61 (1999).
   PubMed Web of Science ®Google Scholar
• Amiral J, Bridey F, Wolf M et al Antibodies to macromolecular platelet Factor 4—heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb. Haemost. 73,21–28 (1995).
   PubMed Web of Science ®Google Scholar
• Newman PM, Swanson RL, Chong BH. Heparin-induced thrombocytopenia: IgG binding to PF4—heparin complexes in the fluid phase and cross reactivity with low-molecular-weight heparin and heparinoid. Thromb. Haemost. 80,292–297 (1998).
   PubMed Web of Science ®Google Scholar
• •Describes a sensitive fluid-phase assay for measuring anti-PF4/heparin antibodies.
   Google Scholar
• Wester J. New developments in thrombosis and hemostasis with a focus on critical care medicine. Nederlandse Vereni ging voor Intensive Care 6,20–23 (2002).
   Google Scholar
• Warkentin TE, Heddle NM. Laboratory diagnosis of immune heparin-induced thrombocytopenia. Curr. Hematol. Rep. 2, 148–157 (2003).
   PubMedGoogle Scholar
• Greinacher A, Janssens U, Berg G et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 100,587–593 (1999).
   PubMed Web of Science ®Google Scholar
• ••Reports another important prospectivehistorical controlled trial of lepirudin in HIT patients.
   Google Scholar
• Greinacher A, Völpel H, Janssens U et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia: a prospective study. Circulation 99,73–80 (1999).
   PubMed Web of Science ®Google Scholar
• ••Reports the first prospective historicalcontrolled trial of lepirudin in HIT patients.
   Google Scholar
• Chong BH. Danaparoid for the treatment of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
   Google Scholar
• Chong BH, Magnani HN. Orgaran in heparin-induced thrombocytopenia. Haemostasis 22,85–91 (1992).
   PubMedGoogle Scholar
• Chong BH. Prospective randomized open- label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia. Thromb. Haemost 86,1170-1175 (2001).
   Google Scholar
• ••Reports the first prospective, randomized,controlled trial in the management of thrombosis in HIT patients comparing danaparoid and dextran 70.
   Google Scholar
• Lewis BE, Hursting MJ. Argatroban therapy in heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
   Google Scholar
• Amira1J, Lormeau JC, Marfaing-Koka A et al. Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin—PF4 complexes developed in heparin-induced thrombocytopenia. Blood CoaguL Fibrind 8, 114–117 (1997).
   PubMed Web of Science ®Google Scholar
• Bartholomew J. Bivalirudin for the treatment of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
   Google Scholar
• Eriksson BI, Bergqvist D, Kalebo P et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomized trial. Lancet 360,1441–1447 (2002).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Elavathil LJ, Hayward CP, Johnston MA, Russett JI, Kelton JG. The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med 127, 804–812 (1997).
   PubMed Web of Science ®Google Scholar
• ••Reports the association of limb gangrenewith warfarin therapy in HIT patients.
   Google Scholar
• Greinacher A. Lepirudin for the treatment of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
   Google Scholar
• Greinacher A, Eichler P, Lubenow N, Kiefel V Drug-induced and drug-dependent immune thrombocytopenias. Rev. Clin. Exp. HematoL 5,166–200 (2001).
   PubMedGoogle Scholar
• Lubenow N, Eichler P, Greinacher A. Results of a large drug-monitoring program confirms the safety and efficacy of refludan (lepirudin) in patients with immune-mediated heparin-induced thrombocytopenia (HIT). Blood 100(Suppl.), (2002) (Abstract 502a).
   Google Scholar
• Greinacher A, Eichler P, Lubenow N. Anaphylactic reactions associated with lepirudin in patients with heparin-induced thrombocytopenia (HIT). Circulation 108, 2062–2065 (2003).
   PubMed Web of Science ®Google Scholar
• •Reports that anaphylactic reactions, although rare, can occur in HIT patients treated with lepirudin.
   Google Scholar
• Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org. 10172). Thromb. Haemost. 70,554–561 (1993).
   PubMed Web of Science ®Google Scholar
• ••Describes a large clinical experience ofdanaparoid treatment in HIT patients.
   Google Scholar
• Meuleman DG. Orgaran (Org. 10172): its pharmacological profile in experimental models. Haemostasis 22,58–65 (1992).
   PubMedGoogle Scholar
• Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Semin. Hematol. 35(4 Suppl. 5), 3–8 (1998).
   Google Scholar
• Warkentin TE. Danaparoid (orgaran) for the treatment of heparin-induced thrombocytopenia (HIT) and thrombosis: effects on in vivo thrombin and cross-linked fibrin generation and evaluation of the clinical significance of in vitro cross reactivity of danaparoid for HIT-IgG. Blood 88, (1996) (Abstract 626a).
   Google Scholar
• Tardy/Poncet B, Mahul P, Beraud AM, Favre JP, Tardy B, Guyotat D. Failure of orgaran therapy in a patient with a previous heparin-induced thrombocytopenia. Br. J. Haematol 90, 69–70 (1995).
   Web of Science ®Google Scholar
• Lewis BE, Wallis DE, Berkowitz SD et al Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 103, 1838–1843 (2001).
   PubMed Web of Science ®Google Scholar
• ••First report of a prospective, historical,controlled trial of argatroban in the treatment of HIT.
   Google Scholar
• Lewis BE, Wallis DE, Leya F, Hursting MJ, Kelton JG. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch. Intern. Med 163, 1849–1856 (2003).
   PubMed Web of Science ®Google Scholar
• ••Report of another prospective, historical,controlled trial of argatroban in the treatment of HIT.
   Google Scholar
• Robson R, White H, Aylward P, Frampton C. Bivalirudin pharmacokinetics and pharmacodynamics: effect of renal function, dose and gender. Clin. Pharmacol Ther 71, 433–439 (2002).
   PubMed Web of Science ®Google Scholar
• Chamberlin JR, Lewis B, Leya F et al. Successful treatment of heparin-associated thrombocytopenia and thrombosis using hirulog. Can. J. Cardia 11, 511–514 (1995).
   Google Scholar
• •Reports the treatment of HIT with bivalirudin.
   Google Scholar
• Francis JL, Drexler A, Gwyn G, Moroose R. Bivalirudin, a direct thrombin inhibitor, in the treatment of heparin-induced thrombocytopenia. Thromb. Haemost. (Suppl. 1) (2003) (Abstract 1909).
   PubMedGoogle Scholar
• Boneu B, Necciari J, Cariou R. Pharmacokinetics and tolerance of the natural pentasaccharide (0RG31540/5R90107A) with high affinity to antithrombin III in man. Thromb. Haemost. 74, 1468–1473 (1995).
   PubMed Web of Science ®Google Scholar
• Buller HR, Davidson BL, Decousus H et al, and the Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J. Med. 349, 1695–1702 (2003).
   PubMed Web of Science ®Google Scholar
• Johansson LC, Frison L, Logren U, Fager G, Gustafsson D, Eriksson UG. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin. Pharmacokinet. 42, 381–392 (2003).
   PubMed Web of Science ®Google Scholar
• Olsson SB, and the Executive Steering Committee on behalf of the SPORTIF III Investigators. Stroke prevention with oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. Lancet 362, 1691–1698 (2003).
   PubMed Web of Science ®Google Scholar
• Cohen JI, Cooper MR, Greenberg GS. Streptokinase therapy of pulmonary emboli with heparin-associated thrombocytopenia. Arch. Intern. Med 145, 1725–1726 (1985).
   PubMedGoogle Scholar
• Sobel M, Adelman B, Szentpeterey S, Hofmann M, Posner MB Jenvey W Surgical management of heparin-associated thrombocytopenia. Strategies in the treatment of venous and arterial thromboembolism. J Vasc. Swg. 8, 395–401 (1988).
   PubMed Web of Science ®Google Scholar
• Thorp D, Canty A, Whiting J et al Plasma exchange and heparin-induced thrombocytopenia. Prog Clin. Bid Res. 337, 521–522 (1990).
   PubMedGoogle Scholar
• Grau E, Linares M, Alaso MA, Ruvira J, Sanchis J. Heparin-induced thrombocytopenia — response to intravenous immunoglobulin in vivo and in vitro. Am. J Hematol 39, 312 (1992).
   PubMed Web of Science ®Google Scholar
• Gruel Y, Lermusiaux P, Lang M et al Usefulness of antiplatelet drugs in the management of heparin-associated thrombocytopenia and thrombosis. Ann. Vasc. Surg. 5, 552–555 (1991).
   PubMedGoogle Scholar
• Chong BH, Murray B, Berndt MC, Dunlop LC, Brighton T, Chesterman CN. Plasma P-selectin is increased in thrombotic consumptive platelet disorders. Blood 83, 1535–1541 (1994).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am. J. Med Sci. 101, 502–507 (1996).
   Google Scholar
• Poetzsch B, Madlener K Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
   Google Scholar
• Merry AF, Raudkivi PJ, Middleton NG et al Bivalirudin versus heparin and protamine in off pump coronary artery bypass surgery. Ann. Thorac. Surg 77(3), 925–931 (2004).
   PubMed Web of Science ®Google Scholar
• Kappa JR, Fisher CA, Todd B et al Intraoperative management of patients with heparin-induced thrombocytopenia. Ann. Thorac. Surg 49, 714–722 (1990).
   PubMed Web of Science ®Google Scholar
• Laster J, Elfin R, Silver D. Re-exposure to heparin of patients with heparin-associated antibodies. Vasc. Surg 9, 677–681 (1989).
   Google Scholar
• Lewis BE, Matthai WH Jr, Cohen M, Moses JW, Hursting MJ, Leya F, ARG-216/310/311 Study Investigators. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Catheter Cardiovasc. Interv. 57, 177–184 (2002).
   PubMed Web of Science ®Google Scholar
• •Reports on a prospective study of argatroban in patients undergoing percutaneous coronary intervention.
   Google Scholar
• Jang I-K, Matthai WH, Kleiman NS. Combination of a direct thrombin inhibitor, argatroban, and glycoprotein Ifb/IIIa inhibitor is effective and safe in patients undergoing percutaneous coronary intervention. J. Am. Coll Cardiol 91(Suppl.) (2003) (Abstract 68a).
   Google Scholar
• OASIS Investigators. Comparison of the effects of two doses of recombinant hirudin compared with heparin in patients with acute myocardial ischaemia without ST elevation: a pilot study. Circulation 96, 769–777 (1997).
   PubMed Web of Science ®Google Scholar
• OASIS-2 Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia wihtout ST elevation: a randominzed trial. Lancet 353, 429–438 (1999).
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Lewis BE, Wildermann NM et al, and the ATBAT Investigators. The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J Invasive Cardiol 15(11), 611–616 (2003).
   PubMedGoogle Scholar
• Fischer KG. Hemodialysis in heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. Warkentin TE, Greinacher A (Eds), Marcel Dekker, NY, USA (2004).
   Google Scholar